|Bid||54.79 x 800|
|Ask||58.12 x 1400|
|Day's Range||55.59 - 57.02|
|52 Week Range||50.38 - 72.72|
|Beta (5Y Monthly)||1.97|
|PE Ratio (TTM)||14.74|
|Earnings Date||Apr 25, 2022 - Apr 29, 2022|
|Forward Dividend & Yield||0.60 (1.06%)|
|Ex-Dividend Date||Mar 14, 2022|
|1y Target Est||79.64|
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
- $209.7 Million Cash and Cash Equivalents at March 31, 2022 – - Over 120 Patients Now Enrolled in Phase 3 Program - AUSTIN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the first quarter ended March 31, 2022 and provided a clinical update on its Phase 3 clinical program of simufilam in Alzheimer’s disease. Simufilam is Cassava Sciences’ lead drug candida
Boyd Gaming Corporation ( NYSE:BYD ), is not the largest company out there, but it received a lot of attention from a...